Elixigen
CompanySouth Korea
Elixigen develops one asset, in phase 2 (NG101 in wet age-related macular degeneration). Mostly gene therapy; based in South Korea.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 1
- Signal
Pipeline
1Phase 2, Gene therapy, wet age-related macular degeneration
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Signals1
- Similar companies2